Although not statistically significant, the present study observed a slight increase in pAkt expression, further supporting the hypothesis that the chosen EVR dose did not impair the Akt pathway and therefore, did not induce anxiety- or depression-like symptoms. This evidence concerns the gene AKT1 and depressive disorder.